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Methane Negative Chemical
Ionization Analysis of 1,3-Dihydro-5-
phenyl-1,4-benzodiazepin-2-ones
by W. A. Garland* and B. J. Miwa*
The methane negative chemical ionization (NCI) mass spectra ofthe medically important 1,3-
dihydro-5-phenyl-1,4-benzodiazepin-2-ones generally consisted solely ofM- and (M-H)- ions.
Attempts to find the location ofthe H lost in the generation ofthe (M-H)- ion were unsuccess-
ful, although many possibilities were eliminated. A Hammett correlation analysis ofthe relative
sensitivities of a series of 7-substituted benzodiazepines suggested that the initial ionization
takes place at the 4,5-imine bond. For certain benzodiazepines, the (M-H)- ion generated by
methane NCI was 20 times more intense than the MH+ ion generated by methane positive
chemical ionization (PCI). By using NCI, a sensitive and simple GC-MS assay for nordiazepam
was developed that can quantitate this important metabolite ofmany ofthe clinically used ben-
zodiazepines in the blood and brain of rats.
Introduction
Compounds with the general 1,3-dihydro-5-phe-
nyl-1,4-benzodiazepin-2-one structure (Table 1)
are extensively used in medicine as anxiolytic
(Valium, Librium, Serax, Ativan, Verstran, Tran-
xene), anticonvulsant (Clonopin) and hypnotic
(Dalmane, Mogadon, Rohypnol) agents (1). Be-
cause of the high potency of these compounds and
their large volume of distribution (2), they are
present, following dosing, at relatively low con-
centrations in blood.
Fortunately for analytical purposes, most of
these compounds have suitable characteristics for
analysis by gas chromatography (GC) and ex-
cellent electron capture (EC) properties. Thus,
most assays for these compounds have used EC-
GC to obtain the required sensitivity (3-5). How-
ever, in certain circumstances, eg., with the small
volume of blood available from children or infants
with epilepsy or with blood from single-dose ex-
periments, the sensitivity using EC-GC is often
insufficient. In addition, the EC-GC assays are of-
ten difficult to use in the analysis of these chem-
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icals at their site of action, brain tissue, because
of interference from coeluting substances.
For these reasons, i.e., the need for greater sen-
sitivity and specificity, we investigated the appli-
cability of the NCI technique, which has been pio-
neered by Dougherty and Hunt (6-9), to the
analysis of the 1,3-dihydro-5-phenyl-1,4-ben-
zodiazepin-2-ones. From a consideration of their
EC response, this class of compounds should be
ideally suited to analysis by EC-NCI. Recently,
we modified our PCI GC-MS assay for Clonopin to
measure this compound by EC-NCI (10). For
Clonopin, we found NCI to be approximately
twenty times more sensitive than PCI with less
complex ion chromatograms. To date, NCI assays
have been published for melatonin (11) and 2,3
dibromopropanol (12).
In this paper, we report the NCI mass spectra
of a number of substituted 1,3-dihydro-5-phenyl-
1,4-benzodiazepin-2-ones, a study of their EC-NCI
sensitivity as a function of structure and a GC-
NCI-MS assay for nordiazepam, a common me-
tabolite of many clinically used benzodiazepines.
The assay's limit of sensitivity is 1 ng or less of
nordiazepam in either 1 g of rat brain or 1 ml of
rat blood.
November 1980 69Table 1. Structures ofa few clinically used 1,3-dihydro-5-phenyl-1,4-benzodiazepin-2-ones andtheirnumberingsystem.
R, R2 R3 R4 Name Trade name
Cl CH3 H H diazepam Valium
Cl H H H nordiazepam
NO2 H H Cl clonazepam Clonopin
Cl CH2CH2N (CH2CH3)2 H F flurazepam Dalmane
NO2 H H H nitrazepam Mogadon
NO2 CH3 H F flunitrazepam Rohypnol
Cl CH2-CK H2 H H prazepam Verstran
H2
Cl H OH H oxazepam Serax
Cl H OH Cl lorazepam Ativan
Cl H CO2K(KOH) H clorazepate Tranxene
Cl CH3 OH H temazepam Levanxol
Material and Methods
Instrumentation
Selected ion monitoring measurements were
made using a Finnigan model 3200 quadrupole
mass spectrometer equipped with a Finnigan Pro-
mim peak monitor. Mass spectra were obtained
using a Finnigan model 1015 quadrupole mass
spectrometer and Finnigan model 6000 data sys-
tem. Both mass spectrometers were coupled to a
Finnigan model 9500 gas chromatograph and
were modified to detect negative ions using the
method of Stafford et al, (13). The conversion dy-
node was a dynode from a Finnigan discrete
stage electron multiplier. The voltage to the con-
version dynode was typically +2500 V. The elec-
tron multiplier, a Galileo model 4770, was typi-
cally operated at -1800 V. Separate power
supplies were used to provide the ion energy and
lens voltages. The trap and ion repeller were elec-
trically tied to the ion energy. A 600 gauss mag-
net was placed outside the vacuum on the quad-
rupole housing either above the ion source
(Finnigan 3200) or above the electron multiplier
(Finnigan 1015). The magnet was moved until
the small methane NCI background signal at m/e
35 (3Cl) was at a maximum. The ion energy and
lens voltages and the quadrupole rod polarity
were set to give the most intense signal consis-
tent with useful peak shape and unit mass resolu-
tion. The filament emission and electron energy
were set to their lowest values consistent with
maximum negative ion production. The ion source
temperature was between 90 and 130°C.
Each Promim channel was operated with a 100
msec dwell time, a 0.5 Hz frequency response, and
a gain of 108 V/A. Ion chromatograms were re-
corded on a four pen Rikadenki recorder using a
paper speed of 2 cm/min. To record mass spectra,
the model 6000 data system set the mass spec-
trometer to scan every 2 sec between m/e 10 and
m/e 410 with a 5 msec/amu integration time. The
signal threshold was set at 1 bit.
The GC column, 4 ft x 2 mm inside diameter,
was packed with 3% OV-17 on 120-140 mesh Gas
Chrom Q (Applied Science Laboratories). Prior to
use, the column was conditioned at 300°C over-
night with a 20 ml/min nitrogen flow. For the as-
say the temperature of the injector, the column
oven, the separator oven, and the source re-en-
trant tube were 300, 280, 250, and 250°C, respec-
tively. Methane was used both as GC carrier gas
(10 psi) and CI reagent gas. Under these condi-
tions the retention time of nordiazepam was 120
sec.
For both GC-MS and direct insertion probe
(DIP)-MS determinations, the methane ion
Environmental Health Perspectives 70source pressure was 0.3-0.5 torr. This value was
determined by MacLeod gauge connected to the
ion source by a modified DIP.
Materials
Heptane, acetone, methanol, and dichlorome-
thane were all of nanograde quality (Burdick and
Jackson). 1,2-Dichloroethani was analytical grade
(Fisher Scientific). The preparation of 1M pH 10
borate buffer has been described (14). Water was
distilled. Methane (ultra high purity) was ob-
tained from Matheson Gas Products. Culture
tubes with Teflon-lined screw caps (16 ml, Pyrex
9825) were used for the blood or brain homoge-
nate extractions. Centrifuge tubes (5 ml, Pyrex
8061) were used for evaporation of the extracting
solvent. Prior to use, all glassware was cleaned
with detergent, treated with a 1% aqueous solu-
tion of Prosil-28 (PCR Research Chemicals) and
consecutively rinsed with water, dichloromethane
and methanol.
Unlabeled and deuterated benzodiazepines
were obtained from Drs. W. Scott and A. Lieb-
man, respectively, of the Chemical Research De-
partment, Hoffmann-La Roche Inc., Nutley, N. J.,
07110. Stock solutions (mg/ml) of all compounds
were prepared in methanol. For the assay, several
methanolic workingsolutions were prepared from
the mg/ml stock solution of nordiazepam and
[2',6'-2H]-nordiazepam (nordiazepam-d2). Solu-
tions A-F contained 0, 100, 250, 500, 1000 and 2000
ng/ml of nordiazepam, respectively, and 2000 ng/
ml of nordiazepam-d2.
Sprague Dawley male rats (250 g) were pur-
chased from Charles River Inc. and were caged
and fed for one week prior to use. The dosing so-
lution (10 mg/ml) was prepared by dissolving
nordiazepam in polypropyleneglycol. Three rats
were given a 10 mg/kg oral injection of this solu-
tion. At the designated times the rats were
anesthetized with ethyl ether, and blood was re-
moved by open chest cardiac puncture. The blood
was placed in a culture tube containing a small
amount of heparin and frozen at -15°C. The rats
were then decapitated and their brains removed.
The brains were wrapped in aluminum foil, frozen
on Dry Ice, and stored at -15°C.
Nordiazepam Assay Procedure
The frozen brains were weighed and homogenized
(Tekmar tissumizer, 20sec, 90 rpm) in 5 ml of wa-
ter/ethanol (1:1). The cold blood sample tubes
were placed in hot water until the blood thawed.
Either 1 ml of blood or 1 ml of the brain homoge-
nate was transferred to a 16 ml culture tube. To
the tube was added 200 ng of nordiazepam-d2 (0.1
ml of solution A) and 2 ml of 1M pH 10 borate
buffer. The mixture was vortexed on a Vortex
Genie, 6 ml of a solution of 20% 1,2-dichloroethane
in benzene was added, and the sample was ex-
tracted by gently shaking for 30 min on a Eber-
bach variable speed reciprocating shaker. The
tube was centrifuged (Damon model CRU-500) at
10°C for 10 min at 1500g. The organic phase was
transferred by using a Pasteur pipet to a 5 ml
centrifuge tube and the solvent removed at 60°C
with a gentle stream of nitrogen (N-Evap, Or-
ganomation Assoc.). The residue was reconsti-
tuted in 100 ,ul of a solution of 10% acetone in hep-
tane; 1-3Al of this solution was then injected into
the GC-MS. Approximately 45 sec after sample in-
jection, the GC divert valve was closed to allow
the GC effluent to enter the ion source. The ion
source supplies were turned on 5 sec later.
Prior to injecting any samples, the GC-column
was treated with several injections of the re-
constituted residue from drug free rat brain ex-
tracts. Several 1 ,ul injections of solution F were
made to tune the mass spectrometer by using the
Promim, to monitor m/e 269, the (M-H)- ion of
nordiazepam, and m/e 273, the 37CI isotope variant
of the (M-H)- ion of nordiazepam-d2. Additional
injections of the same solution were made to find
the optimum ion source voltages and the precise
column oven temperature which gives nordiaze-
pam a retention time of 120 sec. Aliquots of solu-
tions A-F were then injected. A 0.1 tdl injection of
solution F should give a response at m/e 269 with
a signal-to-noise ratio greater than 100. If this is
not true, either the column needs to be replaced or
the ion source and/or quadrupole rods need clean-
ing. Injection of 1 ,l of solution A should give a
response at m/e 269 which is less than 2% of the
response at m/e 273. Injection of 5 ,l of the 10%
acetone in heptane solvent mixture should give no
significant response at m/e 269 or 273.
The peak heights in the ion chromatogram were
measured with a ruler and the m/e 269 to m/e 273
ion ratio calculated. The ratio was converted to a
compound amount using a standard curve. The
standard curve was generated from the analyses
of the ion ratio versus nordiazepam added data
from 1 ml specimens of either drug-free brain ho-
mogenate or drug-free blood each spiked with 100
IlI of either solution A (0 ng), B (10 ng), C (25
ng), D (50 ng), E (100 ng), or F (200 ng). The
data from the standards were fitted by a non-
linear least squares procedure to the standard iso-
tope dilution equation (15, 16). The constants
from the least-squares fitting were used to calcu-
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FIGURE 1. Methane NCI mass spectrum of 7-fluoro-1,3-dihydro-5-phenyl-1,4-benzodiazepin-
2-one (MW = 254).
late the concentration of nordiazepam in an un-
known sample given a measured ion ratio.
Results and Discussion
The NCI mass spectrum of 7-fluoro-1,3-dihydiro-
5-phenyl-1,4-benzodiazepin-2-one, shown in Fig-
ure 1, is representative of that obtained from this
class of compound. The spectrum is quite simple,
consisting principally of an intense (M-H).- ion
and a much smaller M- ion with virtually no
other, even low molecular weight ions. Strong (M-
H)+ ions are observed in the positive electron io-
nization (PEI) mass spectra of this class of com-
pounds (17), while MH+ ions dominate their
"acid-base" PCI mass spectra.
The M- ion in the NCI spectra tended to be
small except when R1 is NO2 (Fig. 2). In this case,
the M- ion tended to be as intense, or somewhat
more intense, than the (M-H) - ion. At certain
times over the last year, the M- ion for several
compounds N02-substituted at the R1 position was
100 times more intense than their (M-H) - ion. At
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I
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these same times, other 1,3-dihydro-5-phenyl-1,4
benzodiazepin-2-ones also showed enhanced M-
ion. The reason(s) for this is unclear and the
problem is under investigation.
Since several specifically deuterated nordiaze-
pam analogs were available, we tried to locate the
origin of the H' lost in the generation of the (M-
H)- ion. We found that for nordiazepam specifi-
cally deuterated at the 6 position or dideuterated
at the 2',6' positions no significant (e.g., 5%) loss
of deuterium was observed. These results are
quite different than those of Benz and Vane, who
analyzed these same compounds by PEI (18).
These workers found that 55-60% of the H lost to
generate the (M-H)+ ion in the PEI mass spec-
trum came from these positions.
The NCI mass spectra of nordiazepam specifi-
cally deuterated at position 9 or dideuterated at
position 3 were obtained. Again no significant loss
of deuterium was observed.
If the H lost was at position 1, methylation at
the nitrogen should dramatically decrease the ra-
tio of the (M-H)- to M- ions. Instead, we found
56 100 O15 200 250 300 350 400
M/E
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FIGURE 2. Methane NCI mass spectrum of 7-nitro-1,3-dihydro-5-phenyl-1,4-benzodiazepin-2-
one (MW = 281).
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72Table 2. Relative sensitivities ofvarious 7-substituted 1,3-
dihydro-5-phenyl-1,4 benzodiazepin-2-ones.
RlN
R, Direct insertion probe-mS Gc-Ms
Cl 44.3 67.3
COCH3 34.8 31.8
F 30.0 30.9
OCH3 1.5 0.9
H 1.0 1.0
OH 0.9
CH3 0.8 0.5
NH2 0.1 0.2
that diazepam gave approximately the same ratio
of M-H- to MW ions as nordiazepam. To test the
possibility that the influence of the N-methyl wag
being masked by the loss of one of the methyl hy-
drogens, we also obtained the NCI mass spectrum
of [1-C2H3]-nordiazepam. However, this com-
pound's mass spectrum also showed no loss of deu-
N
ci NN
D D
&. &J i . .L _ . ......I.
terium and thus we concluded that the hydrogen
lost was not that at position 1.
No isotope variants of nordiazepam were avail-
able with deuterium at either 3',4', or 5'. However,
[3',4',5',6'-2H]-bromazepam had been synthesized.
HO0
Br'N~~~~~~~~B
Br N~ ~ ~
N'
N Bromazepam [3',4',5'6'-2H]-Bromazepain
The NCI spectrum of unlabeled bromazepam was
dominated by generation of a Br- ion. Fortu-
nately, the spectrum also contained a (M-H)- ion
with an intensity approximately 5% of the in-
tensity of the Br- ion and virtually no M ion.
Consistent with the noninvolvement of the hydro-
gens at the 3', 4' or 5' positions in (M-H) - ion for-
mation, the spectrum of [3',4',5',6'-2H]-bromaze-
pam showed the loss of H, but no loss of
deuterium.
By elimination, the 8-position is left as the loca-
tion of the H lost. We are currently synthesizing
nordiazepam deuterated at the 8-position to check
27
L.A . . .- ..p.
November 1980
I
W I
W T . -T
- . . . . . I . I
10N 150 200 250 300
FIGURE 3. Methane NCI mass spectra of nordiazepam (upper spectrum, MW = 270) and
nordiazepam-d2 (lower spectrum, MW = 272).
L .
W
L
73A B
=l '1-K L~~~~~IT/E2M
FIGURE 4. Ion chromatograms from the analysis of (A) 1 ml of
rat brain homogenate and (B) 1 ml of rat blood, each spiked
with 1 ng of nordiazepam and 10 ng of nordiazepam-d2.
this possibility. In addition, we are synthesizing
nordiazepam specifically deuterated at the 3', 4',
and 5' positions to verify the conclusion inferred
from the deuterated bromazepam mass spectrum.
If these compounds fail to establish the origin of
the H lost, we may have to radically change our
view of the nature of the (M-H) - ion.
It became apparent, after obtaining spectra on
several benzodiazepines, that the NCI sensitivity
of the various compounds varied greatly. In par-
ticular, the sensitivity varied as a function of the
nature of the substituent at R,. For instance nor-
diazepam was approximately 400 times more sen-
sitive than 7-amino-1,3-dihydro-phenyl-1,4-benzo-
diazepin-2-one, when both compounds were ana-
lyzed by DIP-NCIMS. By methane PCI analysis,
on the other hand, the sensitivities of both the
compounds were approximately equal.
The NCI sensitivities of various 7-substituted
1,3-dihydro-5-phenyl-1,4-benzo-diazepin-2-ones
74
relative to the 7-H compound are given in Table 2.
Each data point was the average of two measure-
ments of the intensity of all ions in the NCI mass
spectra. Duplicate measurements were within
20% of one another. We could not chromatograph
the compound with R1 equals OH and this com-
pound was not included as a data point in the GC-
MS sensitivity comparison. The GC-MS analyses
were performed by using the column and GC con-
ditions described in the experimental section for
the nordiazepam assay. The compound with a 7-
NO2 substituent gave erratic sensitivity and was
not included. We attributed the variation to the
tendency of this type of compound to undergo re-
duction in the CI ion source (19).
The logarithm of the relative sensitivities in
Table 2 were highly correlated with the Hammett
a,,t values of the R1 substituent (20). The equation,
y = (m ± SD) (x) + (b ± SD), for the u,,, correla-
tion was log (relative sensitivity) = (10.3 ± 0.74)
(Gmeta) + (-0.2 ± 0.18). The correlation coefficient
for the fit was 0.97. The correlation coefficient for
the fit with the Hammett ,.ra values of the R,
substituent was only 0.82. The functional group
meta to the 7-position is the 4,5 imine bond and
our data suggests that this bond is the site of elec-
tron capture. This bond is also the suspected site
of ionization in the polarographic analysis of 1,3-
dihydro-5-phenyl-1,4-benzodiazepin-2-ones (21).
The suggestion that the imine bond is the site of
ionization is also supported by the effect of fluor-
ine substitution in the 5-phenyl ring on NCI sen-
sitivity. Compared to the sensitivity of nordiaze-
pam, 3'-fluoronordiazepam was found to be
significantly more sensitive than 4'-fluoronor-
diazepam. This is consistent with ionization at the
3
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FIGURE 5. Typical standard curve from the analysis of (x)
blood and (0) brain homogenate, each spiked with various
amotnts of nordiazepam and 200 ng of nordiazepam-d2.
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FIGURE 6. Ion chromatograms from the analysis of (A) brain
and (B) blood from a rat sacrificed 60 min after receiving a
10 mg/kg dose of nordiazepam.
imine bond, since the a values for meta and para
fluoro substituents are 0.34 and 0.06, respectively
(20). Thus, our study suggests that the more elec-
tron-deficient the imine bond, the higher the reac-
tion rate of the compound with the thermal elec-
trons in the source or the lower the rate of the
reverse autodetachment reaction, i.e. the more
stable the generated anion.
We were hoping that a brain tissue assay for
nordiazepam could be developed by using the NCI
technique. This compound is a key product in the
metabolism of Valium, Nobrium, Tranxene, Ati-
van, and Verstran and has itself been used as a
hypnotic agent (21). Attempts to analyze this
compound using PCI with a simple sample
workup were unvariably frustrated by the pres-
ence of interfering substances, especially lipids,
in the biological extracts. The results using NCI,
on the other hand, were quite satisfying.
The methane NCI mass spectra of nordiazepam
and nordiazepam-d2, the as internal standard in
the assay, can be seen in Figure 3. As expected,
the spectra consist principally of each compounds
(M-H)- ion; m/e 269 and m/e 271 for nordiazepam
and nordiazepam-d2, respectively. For the nor-
diazepam response, m/e 269 was monitored in the
GC effluent. Because of interference from nor-
diazepam's 37Cl isotope peak, the 37C1 isotope peak
of nordiazepam-d2 at m/e 273 was monitored in
the assay for the internal standard response.
Typical ion chromatograms from the assay are
shown in Figure 4. Ion chromatograms A and B
were from the analysis of 0.3 g of control rat
brain and 1 ml of control rat blood, respectively,
each spiked with 1 ng of nordiazepam and 10 ng
of nordiazepam-d2. Both chromatograms were ob-
tained from the injection of 1 out of the available
100tl. Thus the response at m/e 269 represents
approximately 10 pg injected on column. From
the injection of many standard solutions over a
period of several months, we estimate that the
methane NCI sensitivity of nordiazepam is 15-25
times the compounds' methane PCI sensitivity.
Ion chromatogram A is remarkable. It illus-
trates that the sensitivity and specificity of the
nci technique will permit the determination of
low concentrations of a compound with intrinsic
electron capture properties, e.g. nordiazepam, in a
complex matrix like brain tissue with relatively
simple sample workup.
A typical standard curve from the assay is
shown in Figure 5. Because of nordiazepam's
small response at m/e 273, the mass of the ion
being monitored for the internal standard, the
curve is nonlinear (23). As is our practice in such
cases (15, 16), the standard curve was analyzed by
a nonlinear least-squares fitting of the ion ratio
versus amount added data to the isotope dilution
equation R = (x + A)/(Bx + C). In this equation
R is the m/e 269 to m/e 273 ion ratio and x is the
amount added. For the curve shown in Figure 5,
the calculated constants (+ SD) were A = 3.8 ±
2.2 ng, B = 0.13 + 0.02, and C= 54.8 ± 4.5 ng. An
unknown amount (x) can be determined from an
ion ratio (R) by using the rearranged equation x
- (RC-A)/(1-RB).
Ion chromatograms from the analysis of the
brain homogenate (A) and blood (B) from a rat
Table 3. Brain and blood concentrations ofnordiazepam in
three rats sacrificed atvarioustimes afterreceiving a 10 mg/
kgoral dose ofnordiazepam.
Blood Brain
Time after concentration, concentration,
dose, min ng/ml ng/g
20 45 147
40 32 66
60 13 29
November 1980 75sacrificed 60 min after receiving a 10 mg/kg oral
dose of nordiazepam are shown in Figure 6. For
both determinations, 1 of 100 1d were injected.
The measured blood and brain homogenate con-
centrations were 13 and 11 ng/ml, respectively.
Brain and blood concentrations of nordiazepam
in rats sacrificed at 20, 40 and 60 minutes after re-
ceiving a 10 mg/kg oral dose of nordiazepam are
shown in Table 3. The mean (+ SD) brain to blood
concentration, equating 1 g of brain tissue to 1 ml
of blood, was 2.52 + 0.66.
The significance of this work can be simply
stated. (1) In general, the methane mass spectra
of compounds with the 1,3-dihydro-5-phenyl-1,4
benzodiazepin-2-one structure consist of only
(M-H)- and M- ions. The position of the H lost
to generate the (M-H)- ion is unknown, although
many possibilities have been eliminated. (2)A
correlation of the relative sensitivities of a series
of 1,3-dihydro-5-phenyl-1,4-benzodiazepin-2-ones
with structural features suggests that electron
capture takes place at the 4,5 imine bond. (3) Be-
cause of the unique sensitivity and specificity of
NCI, nordiazepam, an important metabolite of
many of the clinically used benzodiazepines, can
be determined in rat brain and blood with rela-
tively simple sample workup.
The authors would like to acknowledge manyhelpful conver-
sations concerning NCI instrumentation with Dr. G. Stafford,
Finnigan Corporation. Dr. S. Markey, National Institutes of
Health, suggested the use of magnets above the ion source
and electron multiplier.
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